MedTrace Logo

Male Sexual Health Questionnaire (MSHQ) - Sexual Function Study

NCT00427882 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 125

Last updated 2007-11-29

No results posted yet for this study

Summary

Primary:

To assess improvement in ejaculation from baseline to the end of treatment (Week 12 or premature withdrawal) with Alfuzosin 10mg OD, using MSHQ score.

Secondary:

* To evaluate sexual function improvement
* To evaluate LUTS (Lower Uninary Tract Symptoms) improvement
* To evaluate the association between LUTS severity and sexual function.
* To assess the safety and the tolerability of Alfuzosin 10mg OD.

Conditions

  • Prostatic Hyperplasia

Interventions

DRUG

ALFUZOSIN

Sponsors & Collaborators

  • Handok Inc.

    lead INDUSTRY

Principal Investigators

  • Hyou-Young Rhim, Dr. · Handok Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Completion
2007-05-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00427882 on ClinicalTrials.gov